News Focus
News Focus
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

Re: genisi post# 2082

Wednesday, 01/21/2009 5:06:00 PM

Wednesday, January 21, 2009 5:06:00 PM

Post# of 3595

Gal cites the following risks to Teva: deterioration of Copaxone revenue due to rapid adoption of Tysabri in 2008 or rapid success of a Paragraph IV challenge on Copaxone

At this point, the latter is a bigger problem than the former, IMO.

I wonder why Gal doesn’t say anything about Truvada.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TEVA News